Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model.
Preparation for an H5N1 influenza pandemic in humans may involve priming the population with a vaccine produced from an existing, available H5N1 strain. We have used a mouse challenge model to compare the immunogenicity and efficacy of inactivated, Vero cell-derived, whole virus H5N1 vaccines in single immunization and homologous or heterologous prime-boost regimes. A single immunization was sufficient to protect against a lethal challenge with strains from matched and unmatched H5N1 clades. Homologous and heterologous prime-boost regimes induced cross-neutralizing antibodies and cross-protection against representative viruses of H5N1 clade 1, clade 2.1, clade 2.2 and clade 2.3. Moreover, the results indicate that heterologous prime-boost immunization regimes might broaden the specificity of the anti-H5N1 antibody response.
Sabarth
Nicolas
N
Baxter BioScience, Biomedical Research Centre, Uferstrasse 15, A-2304 Orth/Donau, Austria.
Howard
M Keith
MK
Savidis-Dacho
Helga
H
van Maurik
André
A
Barrett
P Noel
PN
Kistner
Otfried
O
D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D056738:Cross Protection; D003429:Cross Reactions; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods*; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control*; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000517:prevention & control; D016019:Survival Analysis; D014611:Vaccination / Q000379:methods*
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D007252:Influenza Vaccines